National Heart, Lung, and Blood Institute (NHLBI)
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, National Heart, Lung, and Blood Institute (NHLBI) sits in the top decile of US sponsors by registered trial count (#73 of 15,742 sponsors by registered trial count).
National Heart, Lung, and Blood Institute (NHLBI): 501 sponsored US clinical trials, 62 recruiting.
National Heart, Lung, and Blood Institute (NHLBI) sponsors 501 registered US clinical trials on ClinicalTrials.gov, 62 of them currently recruiting, and 381 completed. 33 of these trials are in Phase 3-4 (later-stage) and 205 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Atherosclerosis, with 12 trials.
Top-decile sponsor footprint
National Heart, Lung, and Blood Institute (NHLBI) ranks in the top decile of sponsors by registered trial count (#73 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
381 of 417 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (91.4%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
501 total, page 8 of 11
Increasing Physical Activity as Part of a Smoking Cessation Program
NCT00403312
The Effect of Exercise on Stem Cell Mobilization and Heart Function in Patients Undergoing Cardiac Rehabilitation
NCT00053456
Identification of Genes Expressed in Atherosclerotic Plaque
NCT00353730
Effects of Nitrite on Blood Vessel Dilation in Normal Volunteers
NCT00048477
Home Use of Automatic External Defibrillators to Treat Sudden Cardiac Arrest
NCT00047411
Acipimox to Improve Hyperlipidemia and Insulin Sensitivity Associated With HIV
NCT00246402
Stem Cell Mobilization to Treat Chest Pain and Shortness of Breath in Patients With Coronary Artery Disease
NCT00043628
Stem Cell Transplant Therapy With Campath-1H for Treating Advanced Mycosis Fungoides and Sezary Syndrome
NCT00047060
Transfer of GPI-Linked Proteins to Transfused Patients With Paroxysmal Nocturnal Hemoglobinuria
NCT00039923
Stem Cell Collection for Adult Volunteers
NCT00033774
Immune Response to Cytomegalovirus
NCT00034437
Alcohol Septal Ablation in Obstructive Hypertrophic Cardiomyopathy: A Pilot Study
NCT00035386
Stem Cell Transplantation and T-Cell Add-Back to Treat Bone Marrow Malignances
NCT00353860
Comparison of Two Programs to Encourage Physical Activity in Individuals With Chronic Obstructive Pulmonary Disease
NCT00328484
Magnetic Resonance Imaging of Narrowed Arteries
NCT00029575
Possible Relation of Toll-Like Receptors and Nitric Oxide to Chronic Lung Disease
NCT00245167
MRI to Detect Embolism Following Angiography and Angioplasty-Stenting of the Renal Artery
NCT00027469
Technical Development of Cardiovascular Magnetic Resonance Imaging
NCT00027170
Collection and Storage of Umbilical Cord Stem Cells for Treatment of Sickle Cell Disease
NCT00012545
A Genome-Wide Scan For Quantitative Trait Loci of Serum Bilirubin - A Framingham Study
NCT00340509
Blood and Marrow Transplant Clinical Research Network
NCT00023530
Nitric Oxide and Transfusion Therapy for Sickle Cell Patients With Pulmonary Hypertension
NCT00023296
The Role of Bacteria and Genetic Variations in Cystic Fibrosis
NCT00043225
Estrogen Replacement to Reduce Risk of Neurologic Injury After Coronary Artery Bypass Graft Surgery
NCT00123539
Tissue Collection From People With Cystic Fibrosis
NCT00015756
Selective T-Cell Depletion to Reduce GVHD (Patients) Receiving Stem Cell Tx to Treat Leukemia, Lymphoma or MDS
NCT00025662
Nitric Oxide Inhalation Therapy to Relieve Chest Pain in Patients With Coronary Artery Disease
NCT00014040
SCH-58235 (Ezetimibe) to Treat Homozygous Sitosterolemia
NCT00045812
Endothelial Progenitor Cells and Risk Factors for Coronary Artery Disease
NCT00013975
Stem Cell Mobilization Potential in Patients With Aplastic Anemia in Remission
NCT00011830
Pirfenidone to Treat Hypertrophic Cardiomyopathy
NCT00011076
Mobilization of Stem Cells With G-CSF for Collection From Patients With Diamond-Blackfan Anemia
NCT00011505
Heart and Skeletal Muscle Problems in Neuroacanthocytosis
NCT00007228
Stem Cell Transplantation to Treat Systemic Mastocytosis
NCT00006413
Phenylbutyrate, Dexamethasone, and Sargramostim in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia
NCT00006240
Identifying Genes That May Increase the Risk for Heart Disease in African Americans
NCT00344136
Factors Associated With Coronary Heart Disease in African Americans in the Jackson Heart Study
NCT00415415
Epsilon-Aminocaproaic Acid to Reduce the Need for Blood Transfusions During and Following Spine Surgery
NCT00320619
Hydroxyurea to Prevent Organ Damage in Children With Sickle Cell Anemia
NCT00006400
Comparison of Hematocrit Levels in Infant Heart Surgery
NCT00006183
Effects of Rosiglitazone on Blood Vessels in Patients With High Blood Pressure and High Cholesterol
NCT00006071
Effects of Angiotensin-Converting Enzyme Inhibitor (Ramipril) Therapy on Blood Vessel Inflammation
NCT00005928
Collection of Liver Tissue for Virologic Studies
NCT00005936
Treatment With Octreotide in Patients With Lymphangioleiomyomatosis
NCT00005906
Mycophenolate Mofetil and Cyclosporine to Treat Relapsing Aplastic Anemia
NCT00005935
An Epidemiological Study of Subjects With Immune Thrombocytopenic Purpura to Evaluate the Relationship Between Platelet Counts, Endogenous Thrombopoietin Levels, Endogenous Anti-Thrombopoietin Antibodies, and Selected Autoimmune Markers
NCT00005570
Determination of Variances in Exhaled Nitric Oxide Output in Normal Healthy Male Volunteers Consuming High and Low Nitrate/Nitrite Diets
NCT00027157
Effects of Hormone Replacement Therapy on Inflammation and Stiffening of Artery Walls
NCT00005108
Combination Therapy of Severe Aplastic Anemia
NCT00001964
School-Based Intervention to Increase Physical Activity Among Adolescent Females
NCT00296101
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 87 |
| Phase 2 | 118 |
| Phase 3 | 29 |
| Phase 4 | 4 |
Therapeutic Areas
What is open in the National Heart, Lung, and Blood Institute (NHLBI) pipeline
62 recruiting of 501 indexed (12% open); 381 completed (76%).
Phase mix: 33 late (III/IV) vs 205 early (I/II) (early-phase heavy).
Top condition: Atherosclerosis (12 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
National Heart, Lung, and Blood Institute (NHLBI): open-pipeline peers nationwide
Peers matched on 501 registered trials and 12% open enrollment, not the therapeutic-area sidebar.
National Heart, Lung, and Blood Institute (NHLBI) sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 501 trials (± recruiting share)
- H. Lee Moffitt Cancer Center and Research Institute · 502 trials · 16% recruiting
- Gilead Sciences · 504 trials · 5% recruiting
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) · 490 trials · 10% recruiting
- Beth Israel Deaconess Medical Center · 488 trials · 14% recruiting
Sponsors near 12% open enrollment (± trial volume)
- Boston University · 12% recruiting · 185 trials
- AstraZeneca · 12% recruiting · 1,285 trials
- Daiichi Sankyo · 12% recruiting · 236 trials
- University of Iowa · 12% recruiting · 228 trials
Related
What to do with this National Heart, Lung, and Blood Institute (NHLBI) page
501 registered trials is a research-attention snapshot, not an endorsement of National Heart, Lung, and Blood Institute (NHLBI) or any single study.
- 62 of National Heart, Lung, and Blood Institute (NHLBI)'s trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Atherosclerosis is the condition National Heart, Lung, and Blood Institute (NHLBI) studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Atherosclerosis trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. National Heart, Lung, and Blood Institute (NHLBI) pipeline card: 501 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.